Canopus BioPharma Incorporated (CBIA)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2022 | 2021 | 2014 | 2013 |
|---|---|---|---|---|
| Operating Cash Flow | -6185.00 | -1755.00 | 1.92 Million | -544.02 Thousand |
| Net Income | -764.7 Thousand | -1755.00 | -850.93 Thousand | -525.93 Thousand |
| Depreciation & Amortization | - | - | -9873.00 | -9873.00 |
| Deferred income taxes | - | - | - | - |
| Stock-based compensation | - | - | - | - |
| Change in working capital | 8397.00 | - | -74.24 Thousand | -12.34 Thousand |
| Other non-cash items | 749.22 Thousand | 1755.00 | 2.86 Million | 4133.00 |
| Investing Cash Flow | - | - | -2.3 Million | 463.65 Thousand |
| Investments in PPE | 5.00 | - | - | - |
| Acquisitions | - | - | - | - |
| Investment purchases | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - |
| Other Investing Activities | - | - | -2.3 Million | 463.65 Thousand |
| Financing Cash Flow | 10.4 Thousand | - | 409.14 Thousand | 80 Thousand |
| Debt repayment | -10 Thousand | - | - | - |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | - | - | - | - |
| Common Stock Issuance | 400.00 | - | 32.5 Thousand | 31.09 Thousand |
| Other Financing Activities | - | - | 376.63 Thousand | 48.9 Thousand |
| Accounts receivables | 900.00 | - | - | - |
| Accounts payables | - | - | - | - |
| Inventory | - | - | - | - |
| Other working capital | 7497.00 | - | -74.24 Thousand | -12.34 Thousand |
| Cash at beginning of period | - | 28.64 Thousand | - | - |
| Cash at end of period | 4215.00 | -1755.00 | 28.54 Thousand | -370.00 |
| Capital Expenditure | 5.00 | - | - | - |
| Effect of forex changes on cash | - | - | - | - |
| Net cash flow / Change in cash | 4215.00 | -30.4 Thousand | 28.54 Thousand | -370.00 |
| Free Cash Flow | -6180.00 | -1755.00 | 1.92 Million | -544.02 Thousand |
| Breakdown | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 FY | 2022 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | -203.94 Thousand | -782.67 Thousand | -782.67 Thousand | -764.7 Thousand | -425.22 Thousand |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | 13.48 Thousand | 124.00 | 124.00 | 8397.00 | 145.00 |
| Other non-cash items | - | 33.43 Thousand | 781.51 Thousand | 781.51 Thousand | 749.22 Thousand | 425 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | 160 Thousand | 160 Thousand | - | 10.4 Thousand | - |
| Debt repayment | - | -160 Thousand | -160 Thousand | - | -10 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | 400.00 | - |
| Other Financing Activities | - | - | 320 Thousand | - | - | - |
| Accounts receivables | - | - | - | - | 900.00 | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | 13.48 Thousand | 124.00 | 124.00 | 7497.00 | 145.00 |
| Cash at beginning of period | - | 3175.00 | 4215.00 | 4215.00 | - | 7886.00 |
| Cash at end of period | - | 6153.00 | 3175.00 | 3175.00 | 4215.00 | 7806.00 |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | 2978.00 | -1040.00 | -1040.00 | 4215.00 | -80.00 |
| Free Cash Flow | - | -157.02 Thousand | -1040.00 | -1040.00 | -6185.00 | -80.00 |
DBGI
SLNG
2515
FRX
ADVLIFE
180640